Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 29, 2025, titled "Strides Delivers a Strong Q1FY26 with ₹11,197m Revenue, ₹2,181m EBITDA, and ₹1,140m Operational PAT".
Press Release Jul 29 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Strides Pharma Science Ltd on 6ix
Earlier from Strides Pharma Science
- Intimation of Board Meeting scheduled on July 29, 2025
- Press Release May 22 2025
- Intimation on Board Meeting scheduled for May 22, 2025
- Press Release Apr 30 2025
- Press Release Jan 30 2025
Later from Strides Pharma Science
- Press Release Sep 08 2025
- Kenox Enters into Strategic Product Development Partnership with Strides
- Press Release Oct 17 2025
- Intimation on Board Meeting scheduled for Oct 31, 2025
- Press Release Oct 31 2025
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science